Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT03576573

Post Market Clinical Follow-Up Study Protocol for PROCOTYL® C Acetabular Components

MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in Europe. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Joint Disease Ankylosis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Bone Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Necrosis Osteoarthritis Osteonecrosis Pathologic Processes Pathological Conditions, Signs and Symptoms Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Elbe Kliniken Buxtehude

Buxtehude, 21614, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

To be included in the study, subjects must meet all of the following criteria:

  • Has previously undergone primary Total Hip Arthroscopy for any of the following:
  • Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia;
  • Inflammatory degenerative joint disease such as rheumatoid arthritis;
  • Correction of functional deformity
  • Subject was implanted with the specified combination of components, namely, any MicroPort Orthopedics or Wright Medical Technology femoral stem and PROCOTYL C Acetabular Components
  • Subject is willing and able to complete required study visits or assessments

Previously implanted bilateral subjects can have both THAs (Total Hip Arthroscopy) enrolled in the study provided:

  • the specified combination of components were implanted in both,
  • all other aspects of the Inclusion/Exclusion Criteria are satisfied,
  • enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and
  • the subject agrees to a second Informed Consent document specific to the second THA. Prospective enrolment of a previously unimplanted hip is not permitted in this study.

Exclusion criteria

Subjects will be excluded if they meet any of the following criteria:

  • Subject was skeletally immature (less than 21 years of age) at time of implantation
  • Subject has a non-MicroPort or non-Wright Medical Technology component implanted (femoral heads, acetabular shells, acetabular liners) in the enrolled Total Hip Arthroscopy
  • Subject is currently enrolled in another clinical investigation which could affect the endpoints of this protocol
  • Subject is unwilling or unable to sign the Informed Consent document
  • Subject has documented substance abuse issues
  • Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study
  • Subject is currently incarcerated or has impending incarceration

Treatment and study plan

PROCOTYL® C

Device

Hip Arthroplasty

Other names: Primary Total Hip Device

Primary outcomes

  1. Component Survivorship

    Time frame: 10 years post-operative

    The primary endpoint is to evaluate component survivorship of the PROCOTYL® C Acetabular Components out to 10 years follow-up. Percentage of hips survived with no revision or replacement at 10-year.

Secondary outcomes

  1. To determine the cumulative incidence of component revision at specified intervals out to 10 years follow-up;

    Time frame: 2-5 years, 5-7 years, and 10 years

    Percentage of hips that were revised or replaced at each of the intervals namely for Early (2-5 years), midterm (5-7 Year), and long-term (10-year) evaluation.

  2. To characterize functional scores, as assessed by Oxford Hip.

    Time frame: 2-5 years, 5-7 years, and 10 years

    The study will be reporting the final Oxford Hip score, which is a summary over 12 items. Each of these items is 5-level Likert scale such as from 'not at all' to 'totally'.

  3. To characterize functional scores, as assessed by EQ-5D-3L scores.

    Time frame: 2-5 years, 5-7 years, and 10 years

    EQ-5D-3L data will be summarized over 5 domains, namely, mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain has 3 levels: no problems, some problems, and extreme problems.

Sponsors and collaborators

Lead sponsor

MicroPort Orthopedics Inc.

Industry

Registry information

Important dates

Study start
2019
Primary completion
2032
Study completion
2032
First posted
Jul 3, 2018
Registry last updated
Nov 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.